Mycoplasma Testing Market Analysis

Mycoplasma Testing Segmentation

Application (Cell Line, Virus Testing, End of Production Testing)

The cell line segment is estimated to gain the largest market share of about ~55% in the year 2035. The growth of the segment is expected due to the rising demand for monoclonal antibodies. For instance, monoclonal antibodies have been proven efficient in constraining COVID-19. Anti-SARS-CoV-2 monoclonal antibodies, such as REGEN-COV, have gained success to prevent infection in domestic contacts and to reduce the risk of hospitalization or death associated with COVID-19. Testing cell lines used for monoclonal antibod production ensures the prevention of mycoplasma contamination and interference with cell growth and antibody expression.

Technique (PCR, ELISA, Microbial Culture, Enzymatic Methods)

The PCR segment is expected to garner a tremendous share of around ~40% in the year 2035. The PCR technique recognizes the various species of mycoplasma by isolating the additional contaminated DNA. The results gained by the PCR (polymerase chain reaction) technique are highly reliant, moreover, the results are quick to achieve and the technique is easy to use.

Our in-depth analysis of the market includes the following segments:

Application	Cell Line Virus Testing End of Production Testing
Technique	PCR ELISA Microbial Culture Enzymatic Methods
Product & Services	Assays, Kits, & Reagents Instruments Services
End User	Biopharmaceutical Company Cell Banks Contract Research Organization (CROs)

Frequently Asked Questions (FAQ)

Increasing expenditure on new biotech research, advancing technology of mycoplasma testing, and globalization of research are the major factors driving the market growth.

The market size of mycoplasma testing is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2023 â€“ 2035.

T he major players in the market are Thermo Fisher Scientific, Inc, Merck KGaA,, Lonza Group Ltd., PromoCell GmbH, Asahi Kasei Corporation, Sartorius AG, InvivoGen, Eurofins Scientific, SwiftDx, and Agathos Biologics.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by application, technique, product & services, end user.

The cell line segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Lack of skilled workers and high cost of testing are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Mycoplasma Testing Market Analysis